Pharmaceutical News

RSS

A biological agent used without chemotherapy appears to offer a disease-free future to patients with rare leukemia

A biological agent — a drug that wraps vitamin A inside bubbles of fat — used without chemotherapy appears to offer as many as one-third of patients with a rare form of leukemia an opportunity for a long-term, disease-free future, say researchers at The University of Texas M. D. Anderson Cancer Center.

7 Jun 2004

Herceptin shows real promise in treatment of HER-2 positive breast disease

According to a study conducted at The University of Texas M. D. Anderson Cancer Center, more than twice as many women with early stage, HER-2 positive breast disease who received Herceptin as part of their pre-surgery chemotherapy had their tumors completely disappear compared to like patients who received only chemotherapy.

7 Jun 2004

Experimental human monoclonal antibody shows striking benefit in patients with advanced melanoma

Early testing of an experimental human monoclonal antibody showed a striking benefit in patients with advanced melanoma, say researchers at The University of Texas M. D. Anderson Cancer Center, who presented their findings at the annual meeting of the American Society of Clinical Oncology.

7 Jun 2004

Investigational drug, LAF237 improved glycemic control in patients with type 2 diabetes

Research presented today showed that the investigational drug, LAF237, the first in a new class, improved glycemic control in patients with type 2 diabetes. In this study, LAF237, which is administered as a tablet to be taken orally, was added to the standard diabetes treatment metformin in patients whose diabetes was not adequately controlled by metformin alone.

7 Jun 2004

Serum estrogen receptor modulator's (SERM's) may help reduce postmenopausal breast cancer risk

Newest research findings were presented on the possible benefits they may provide for postmenopausal breast cancer risk reduction. SERMs are a class of drugs that can block the cell's ability to use estrogen to stimulate the development of breast cancer.

7 Jun 2004

Treatment with atorvastatin cut incidence of stroke by almost a half

Patients with Type 2 diabetes and a CV risk factor would benefit from a cholesterol-lowering medicine according to results from the first ever specifically designed UK primary prevention statin trial announced today at the American Diabetes Association (ADA)2.

7 Jun 2004

Combination treatment may help type 2 diabetes patients

New research presented by Peter Weissman, M.D., from the University of Miami, at the 64th Annual Scientific Sessions of the American Diabetes Association shows that combination treatment with rosiglitazone maleate and metformin significantly improves certain markers of cardiovascular disease risk in patients with type 2 diabetes compared to metformin alone.

6 Jun 2004

Gemcitabine may help breast cancer patients with advanced disease live longer

Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study presented today at the American Society of Clinical Oncology (ASCO) annual meeting.

6 Jun 2004

Multi-targeted anticancer drug shows promise as treatment for metastatic renal cell cancer

A new multi-targeted anticancer drug called SU11248 has shown very promising results in the treatment for metastatic renal cell cancer, one of the most chemotherapy resistant of all cancers.

6 Jun 2004

Velcade major improvement over standard therapy for relapsed multiple myeloma

Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the standard therapy for relapsed disease, researchers at Dana-Farber Cancer Institute report.

6 Jun 2004

Exenatide shows significant improvements in glucose control for people With type 2 diabetes

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company have presented detailed 30-week data from two of the three pivotal Phase 3 studies of exenatide during a late-breaking session at the American Diabetes Association's (ADA) 64th Scientific Sessions in Orlando, Florida.

5 Jun 2004

60,000 set to run in race for the cure

Participants at the Susan G. Komen Breast Cancer Foundation National Race for the Cure® were among the first to view a new breast cancer ribbon today as they descended on the National Mall.

5 Jun 2004

Drug Tarceva improves survival chance for patients with advanced lung cancer

Roche OSI Pharmaceuticals and Genentech today announced that their investigational drug Tarceva(TM) (erlotinib) achieved a significant 42.5% improvement in median survival compared to placebo in patients with advanced non-small cell lung cancer (NSCLC).

5 Jun 2004

Five major prescription drug manufacturers make drugs available to Medicare discount cardholders

The Pharmacy Care Alliance (PCA) today announced that AstraZeneca, Johnson & Johnson Pharmaceutical Companies, Inc., Eli Lilly and Company, Merck and Novartis will make many prescription drugs available to qualifying PCA Medicare discount cardholders free of charges from the manufacturer plus a nominal amount to cover dispensing, processing and other costs.

5 Jun 2004

New generation drug therapy targets the individual

The days of ‘one size fits all’ medicines may soon be a thing of the past for people undergoing radical drug therapies for chronic or serious illnesses.

5 Jun 2004

Drug helps children with attention deficit/hyperactivity disorder (ADHD)

Children with attention deficit/hyperactivity disorder (ADHD) who take 36- or 54-mg doses of once-daily CONCERTA® (methylphenidate HCl) CII are more likely to achieve significantly greater symptom response and symptom reduction than children with ADHD who take CONCERTA 18 mg once daily or near-equivalent doses of methylphenidate three-times-a-day, a study shows.

3 Jun 2004

Antipsychotic compound bifeprunox worth USD 1 billion per year to Solvay and Wyeth

Solvay has re-evaluated the commercial potential of bifeprunox, a Solvay compound in clinical development for the treatment of schizophrenia . Bifeprunox additionally has the potential to be developed in other disorders, i.e. bipolar disorder.

3 Jun 2004

Drug helps patients with metastatic colorectal cancer

A drug designed to cut off a tumor’s blood supply, when paired with a chemotherapy combination, resulted in significant improvement in survival in patients with metastatic colorectal cancer, the first time in decades that survival times have been extended in patients with this devastating form of advanced cancer.

3 Jun 2004

Avastin study shows significant improvement in patients with metastatic colorectal cancer

Genentech, Inc. and Roche have announced that the New England Journal of Medicine published the first Phase III study of an anti-angiogenesis cancer therapy, showing that the addition of Avastin™ (bevacizumab) to the IFL chemotherapy regimen (5-FU/Leucovorin/ CPT-11) significantly extended survival in patients with first-line (previously untreated) metastatic colorectal cancer.

2 Jun 2004

Pharmacy Care Alliance gives out first prescription discounts

Early yesterday morning, two Medicare beneficiaries visited Kroger pharmacies in the Cincinnati area and received the first prescription discounts delivered by the Pharmacy Care Alliance under the Medicare prescription discount card program.

2 Jun 2004

Pharmaceutical News

A biological agent used without chemotherapy appears to offer a disease-free future to patients with rare leukemia

Herceptin shows real promise in treatment of HER-2 positive breast disease

Experimental human monoclonal antibody shows striking benefit in patients with advanced melanoma

Investigational drug, LAF237 improved glycemic control in patients with type 2 diabetes

Serum estrogen receptor modulator's (SERM's) may help reduce postmenopausal breast cancer risk

Treatment with atorvastatin cut incidence of stroke by almost a half

Combination treatment may help type 2 diabetes patients

Gemcitabine may help breast cancer patients with advanced disease live longer

Multi-targeted anticancer drug shows promise as treatment for metastatic renal cell cancer

Velcade major improvement over standard therapy for relapsed multiple myeloma

Exenatide shows significant improvements in glucose control for people With type 2 diabetes

60,000 set to run in race for the cure

Drug Tarceva improves survival chance for patients with advanced lung cancer

Five major prescription drug manufacturers make drugs available to Medicare discount cardholders

New generation drug therapy targets the individual

Drug helps children with attention deficit/hyperactivity disorder (ADHD)

Antipsychotic compound bifeprunox worth USD 1 billion per year to Solvay and Wyeth

Drug helps patients with metastatic colorectal cancer

Avastin study shows significant improvement in patients with metastatic colorectal cancer

Pharmacy Care Alliance gives out first prescription discounts

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News